Cancer immunotherapy, viral therapy research, and biotech innovation by Candel Therapeutics
Candel Therapeutics appoints Martine Zimmermann to board of directors
Candel Therapeutics has announced the appointment of Martine Zimmermann to its board of directors. Zimmermann brings more than 30 years of experience in regulatory affairs and quality management ...
New Candel Therapeutics poster presentations focus on lung cancer and glioblastoma advances
Candel Therapeutics is set to present two poster sessions at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November. The company will share new clinical data from its ...
Candel Therapeutics releases new digital pathology data supporting aglatimagene immune activation in prostate cancer
Candel Therapeutics presented new digital pathology data at a major oncology conference, showing how aglatimagene stimulates immune responses in cases of localized prostate cancer. The company ...
Candel Therapeutics begins late-stage study of aglatimagene to address unmet NSCLC patient need
Candel Therapeutics has initiated a phase 3 clinical trial evaluating aglatimagene for patients with advanced non-small cell lung cancer (NSCLC) who have not responded to immune checkpoint ...
Candel Therapeutics opens enrollment for global phase 3 AURORA trial in advanced NSCLC
Candel Therapeutics has announced that enrollment is now open for its global pivotal phase 3 AURORA trial, evaluating aglatimagene besadenovec in patients with metastatic non-squamous non-small ...
Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec
Candel Therapeutics, Inc. has unveiled new long term follow up data from its phase 3 trial of aglatimagene besadenovec (CAN-2409) targeting localized prostate cancer. Chief Executive Officer Paul ...
Candel Therapeutics 80.4 percent of patients achieve complete response in phase 3 prostate cancer trial
Candel Therapeutics, Inc. announced the publication of its pivotal phase 3 trial results for aglatimagene besadenovec (CAN-2409) in The Lancet Oncology. In the study focusing on localized prostate ...
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs
Candel Therapeutics, Inc. announced that CEO Paul Peter Tak is presenting at the Stifel 2026 Virtual Targeted Oncology Forum. The company is sharing new updates on its clinical pipeline with a ...
Candel Therapeutics Inc presents new extended follow-up phase 3 data for CAN-2409 in prostate cancer
Candel Therapeutics, Inc. announced the release of new extended follow-up data from its phase 3 trial evaluating aglatimagene besadenovec (CAN-2409) in patients with localized prostate cancer. ...
Candel Therapeutics, Inc. celebrates Susan Stewart recognition in RAPSorg milestone honors
Candel Therapeutics, Inc. announced that its Chief Regulatory Officer, Susan Stewart, J.D., has been named to the RAPSorg 50 for 50 list, which honors outstanding regulatory professionals as part ...
Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope
Candel Therapeutics, Inc. CEO Paul-Peter Tak joined a panel at BioEquityEurope focused on Patient Engagement Strategies. During the discussion, Tak outlined how incorporating the patient ...
